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OBJECTIVES: Evaluate costs and beneﬁts of erlotinib in 2nd or
3rd line treatment of advanced or metastatic Non-Small Cell
Lung Cancer (NSCLC) versus docetaxel, pemetrexed or best
supportive care. METHODS: Cost-minimization and cost-
utility analysis were performed for a time horizon of two years
according to a Markov model with 3 health states (“progres-
sion free survival”, “progression” and “death”) and monthly
cycles. Portuguese National Health System (NHS) perspective
was applied. Survival and time to progression were obtained
from 3 clinical trials. Base-case analysis included 2nd and 3rd
line patients with advanced or metastatic NSCLC. Quality
Adjusted Life Years (QALYs) were obtained from a UK study.
Resource consumption was estimated by a Portuguese expert
panel. Costs were calculated according to ofﬁcial Portuguese
database and updated to 2008. Only direct health costs were
applied. Annual discount rate: 5% (cost and utilities). Sensitiv-
ity analysis included different subpopulations, a three years
time horizon and a probabilistic analysis. RESULTS: The cost
per patient was lower with erlotinib (€26,478) versus docetaxel
(€29,262) or pemetrexed (€32,762) and higher versus best sup-
portive care (€16,112). QALYs per patient were higher with
erlotinib (0.250) versus docetaxel (0.225), pemetrexed (0.241)
or best supportive care (0.186). Erlotinib was “dominant” in
the cost-utility analysis, with a lower cost and a higher efﬁcacy
versus docetaxel and pemetrexed. The sensitivity analysis
conﬁrmed the robustness of the base-case analysis results.
CONCLUSIONS: The use of erlotinib instead of docetaxel or
pemetrexed could contribute with annual savings for the NHS
(substitution rates: 5%–65%) that would range between
€135,046–€1,755,602 (docetaxel replacement) and €291,801–
€3,793,409 (pemetrexed replacement), with a gain in terms of
QALYs.
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OBJECTIVES: Few studies have examined the costs associated
with differing ﬁrst-line chemotherapy regimens in patients with
breast cancer. In this study we compared the relative cost
impact of women starting ﬁrst-line chemotherapy with capecit-
abine versus taxane (paclitaxel or docetaxel). METHODS:
Women receiving ﬁrst-line chemotherapy for metastatic breast
cancer from 1998 to 2002 were identiﬁed from a hybrid NC
Medicaid-claims—tumor registry linked database and Medicare
records, and were followed through 2005 with claims data.
T-tests, Chi-square,and Wilcoxon Rank Sum tests, where appli-
cable, were used to compare baseline charactistics between
patients who received ﬁrst-line chemotherapy with capecitabine
versus taxane (paclitaxel or docetaxel). Overall cost impact of
capecitabine was examined using a multivariate log-linear
regression model with propensity scores and other time variant
regressors to account for differences in the two groups of
patients. RESULTS: A total of 733 patients (n = 114 on capecit-
abine and n = 619 on taxanes) starting these 2 ﬁrst-line chemo-
therapies for breast cancer were identiﬁed using the linked
database. While patients starting taxanes had signiﬁcantly
lower health care costs in the pre-index year than patients start-
ing capecitabine (median costs: $19,490 for taxanes versus
$14,315 for capecitabine, p < 0.0001), in the post-index year,
the patients on taxanes experienced signiﬁcantly higher health
care utilization and associated costs compared to patients on
capecitabine (median = $17,792 for capecitabine vs $38,360 for
taxanes, p < 0.0001). The differences were primarily attribut-
able to lower expenses in chemotherapy related claims and less
visit days to outpatient settings for patients on capecitabine.
After adjustment with propensity scores and other confounders,
the capecitabine group was associated with 37.5% lower health
care costs compared to the taxane group (p < 0.0001). CON-
CLUSIONS: In this population-based study, women who
received capecitabine as ﬁrst-line treatment for metastatic
breast cancer had signiﬁcantly lower costs compared to women
starting taxane therapy.
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OBJECTIVES: MBD secondary to cancer can result in serious
and costly SREs. The objective of this study was to characterise
hospital burden associated with MBD and SREs following BC
and PC in the UK. METHODS: Data were analysed from the
CHKS database (Apri, 1, 1999-March 31, 2006), which collects
inpatient episode data for England, Wales, Scotland, and North-
ern Ireland, representing 70% of hospitalizations in the UK.
Patients with an index inpatient admission for either female BC
(ICD-10 C50*) or PC (ICD-10 C61*) between January 4, 2003
and March 31, 2004 were selected for analysis and followed until
March 31, 06 for subsequent admissions of MBD (ICD-10
C79.5*) and SREs (pathological fractures, spinal cord compres-
sions, bone surgery), which were identiﬁed using ICD-10 codes
for diagnoses and OPCS 4.3 codes for procedures. Hospital
length of stay (LOS) and inpatient costs were analysed by cancer
type and disease stage (index, MBD, or SRE). RESULTS: A total
of 38,975 patients were identiﬁed with BC and 28,130 with PC.
The 3-year incidence rates/1000 for hospital admissions, includ-
ing MBD diagnosis code and MBD&SRE diagnosis codes, were
71.7 and 9.2 for BC and 163.5 and 18.6 for PC. Readmissions
were consistent across cancer types, with MBD&SRE patients
having the greatest number of readmissions (BC: 80%; PC: 81%)
compared with patients with cancer diagnosis only (BC: 41%;
PC: 42%) and patients with cancer&MBD (BC: 75%; PC: 73%).
Additionally, patients developing MBD&SREs had greater mean
total LOS (BC: 40 days; PC: 43 days) than those with cancer only
(BC: 8 days; PC: 12 days), and those with cancer&MBD (BC: 24
days; PC: 28 days). Mean cost of admissions increased as the
disease progressed from cancer only to MBD&SREs for BC and
PC patients (£2215–£4158 and £1871–£3618, respectively).
CONCLUSIONS: In general, UK patients with BC and PC, who
develop SREs secondary to MBD consume greater hospital
resources than those with cancer or MBD only.
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